Notice of preliminary results
London, 7 February 2023 - Hikma Pharmaceuticals PLC (Hikma, Group), will announce its preliminary financial results for the year ended 31 December 2022 on Thursday 23 February 2023.
A recording of the 2022 Preliminary Results presentation and slide deck will be available on the Group's website at www.hikma.com from 7:00am GMT. Hikma will also hold a Q&A call for analysts at 11:00am GMT, and a recording will be made available on the Company's website.
To join the call please, please register your attendance in advance by clicking here.
For further information please contact Tiina Lugmayer - tlugmayer@hikma.com.
- ENDS -
Enquiries
Hikma Pharmaceuticals PLC
|
Susan Ringdal EVP, Strategic Planning and Global Affairs |
+44 (0)20 7399 2760/ +44 (0)7776 477050 |
|
Guy Featherstone Associate Director, Investor Relations |
+44 (0)20 3892 4389/ +44 (0)7795 896738 |
|
Layan Kalisse Senior Associate, Investor Relations |
+44 (0)20 7399 2788/ +44 (0)7970 709912 |
Teneo (Press):
Charles Armitstead / Camilla Cunningham +44 (0)7703 330 269/ +44 (0)7464 982426
About Hikma
Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB-/stable S&P and BBB-/stable Fitch)
Hikma helps put better health within reach every day for millions of people around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
